The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Open accessAbstract
Purpose: Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored. Patients and Methods: This was an international, multicenter, open-label, randomized phase II study. Patients (n = 79) with centrally confirmed HER2-negative metastatic breast cancer were randomly assigned to receive pertuzumab once every 3 weeks with a loading dose of 840 mg followed thereafter by either 420 mg (arm A) or 1,050 mg (arm B). Patients were stratified by country and prior taxane therapy. Results: Of 79 patients who were randomly assigned, 78 were included in the intent-to-treat population. In arm A (n = 41), two patients had partial responses, and 18 patients (44%) experienced stable disease (SD) lasting ≥ 12 weeks. In arm B (n = 37), SD was observed in 14 patients (38%). Overall, six of 78 patients responded or had SD ≥ 6 months. Pertuzumab was generally well tolerated, and most adverse events were mild to moderate. Decline in left ventricular ejection fraction of ≥ 10% and/or to less than 50% was observed in eight patients, with one case of congestive heart failure in arm A. Pharmacokinetic data supported a fixed dose of pertuzumab once every 3 weeks. Conclusion: The limited efficacy observed in this study, generally SD of relatively short duration, suggested little benefit of further investigation of single-agent pertuzumab in unselected patients with HER2-negative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Receptor heterodimerization may have a critical role in breast cancers that overexpress multiple members of the HER family.(7-11) Furthermore, dysregulation of HER signaling, including ligand overexpression or abnormal activity, decreased receptor turnover, or receptor mutation can also increase HER signaling activity…”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab in combination with chemotherapy is associated with a survival benefit in patients with both early and metastatic HER2-positive breast cancer.(40-42) However, some patients with HER2-overexpressing breast cancer who progress on trastuzumab may benefit from the addition of pertuzumab to trastuzumab therapy.”
BackgroundSelf-citationUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 3×
“The human epidermal growth factor family of receptors (HER1/EGFR, HER2, HER3, and HER4) mediates cell growth and is dysregulated in many types of cancer.(1-3) Ligand-driven heterodimerization of HER2 with other HER family members leads to downstream signal transduction, which plays an important part in neoplastic tran…”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 2×
“Additionally pertuzumab, but not trastuzumab, inhibited the growth of cancer cells expressing both low/normal and high levels of HER2 in the preclinical setting.(19,38) However, in this study, the measurable therapeutic benefit of pertuzumab in women with HER2-negative breast cancer was mostly in the form of SD of rel…”
BackgroundBiology of HER2 and Its Importance in Breast Cancer
Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 737
Alroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citationMolecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M. (2003) · The Journal of Pathology · doi:10.1002/path.1370 · Cited by 590
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Agero, A. L. C., Dusza, S. W., Benvenuto-Andrade, C., Busam, K. J., Myskowski, P., & Halpern, A. C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.010 · Cited by 381
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Intracellular signaling pathways of ErbB2/HER-2 and family members
Olayioye, M. A. (2001) · Breast Cancer Research · doi:10.1186/bcr327 · Cited by 279
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., Hainsworth, J. D., Garcia, A. A., Pegram, M. D., Schilder, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4221 · Cited by 252
Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer
Baselga, J., Perez, E. A., Pienkowski, T., & Bell, R. (2006) · The Oncologist · doi:10.1634/theoncologist.11-90001-4 · Cited by 222
Self-citationErbB-targeted therapeutic approaches in human cancer
Arteaga, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00104-0 · Cited by 215
Bono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 151
Therapeutic application of anti-growth factor receptor antibodies
Fan, Z., & Mendelsohn, J. M. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199801000-00011 · Cited by 124
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
Hortobágyi, G. N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90108-3 · Cited by 118
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 116
Herbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 102
A review of erlotinib and its clinical use
Tang, P. A., Tsao, M., & Moore, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.2.177 · Cited by 100
Ng, C. M., Lum, B. L., Giménez, V. C., Kelsey, S. M., & Allison, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0205-x · Cited by 99
A new therapeutic antibody masks ErbB2 to its partners
Badache, A., & Hynes, N. E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00088-1 · Cited by 87
The role of cetuximab in the treatment of squamous cell cancer of the head and neck
Burtness, B. A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.8.1085 · Cited by 85
Yamamoto, N., Yamada, Y., Fujiwara, Y., Yamada, K., Fujisaka, Y., Shimizu, T., & Tamura, T. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp006 · Cited by 66
A potential role for activated HER-2 in prostate cancer.
Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., & Sliwkowski, M. X. (2000) · PubMed · Cited by 41
Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell‐by‐Cell Basis
Diermeier‐Daucher, S., Hasmann, M., & Brockhoff, G. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1430.003 · Cited by 18
Cited by
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Self-citationHER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Self-citationPage, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 471
Metadata
- Authors
- Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., Hersberger, V., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-01
- Volume
- 28
- Issue
- 7
- Pages
- 1131-1137
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096111541
- Cited by
- 262
- References
- 36
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.